Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Col... (apies to treat the ninemillion U.S. pati...)

Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration

Date:9/17/2007

apies to treat the nine million U.S. patients diagnosed with IBS-C.

About Chronic Constipation (CC)

As many as 26 million Americans suffer from CC. Patients with CC often experience hard and lumpy stools, straining during defecation, a sensation of incomplete evacuation, and fewer than three bowel movements per week. The discomfort of CC significantly affects patients' quality of life by impairing their ability to work and participate in typical daily activities.

About Linaclotide

Linaclotide is a first-in-class compound currently being tested for the treatment of IBS-C, CC, and other gastrointestinal disorders. Linaclotide is an agonist of guanylate cyclase type-C, a receptor found on the lining of the intestine. In preclinical testing linaclotide was shown to increase fluid secretion into the intestine, accelerate intestinal transit, and decrease visceral pain. Linaclotide was designed to exert its effect on the intestine with minimal systemic exposure. In Phase 2 trials, linaclotide improved bowel function as measured by both complete spontaneous bowel movements and spontaneous bowel movements in patients with CC and IBS-C. Linaclotide is currently being tested for these indications in a pair of Phase 2b trials, which together will enroll 700 patients. A composition of matter patent application is pending for linaclotide, which, if issued would provide protection to 2024, subject to extension.

About Microbia

Microbia (http://www.microbia.com) is an entrepreneurial pharmaceutical company dedicated to the science and art of great drug-making. Three of the Company's drug candidates are in clinical studies-linaclotide for the treatment of IBS-C, CC, and other gastrointestinal disorders; and MD-0727 and MD-3124 for the treatment of hypercholesterolemia. Microbia also has a growing pipeline of additional drug candidates. Microbia Precision Engineering, Inc., a majority-owned subsidi
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Microbial Diversity in Ground and Surface Water Analyzed by Denaturing Gradient Gel Electrophoresis Using the DCode System
2. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
3. Scaling-Up from Spinners, T-Flasks & Shakers: A versatile bioreactor for mammalian and microbial cells
4. DeForest biodiesel plant begins production
5. Biodiesel plant being built in DeForest to make alternative fuel
6. Use of X-rays to advance wood-decay knowledge leads to honor for Forest Products Lab biologist
7. Biodiversity threatened as forests become islands of green, UW professor says
8. BioRobot MDx standardize your automated protocols in clinical laboratories
9. Distance-Learning Remote Laboratories using LabVIEW
10. States are the best laboratories for healthcare reform
11. Scientific Protein Laboratories Acquired by New York firm

Post Your Comments:

Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Col...(apies to treat the ninemillion U.S. pati...)